文献速递细菌感染、耐药与抗菌药物医院感染防控

造血干细胞移植受者定植产超广谱β-内酰胺酶肠杆菌科细菌与菌血症风险

Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.
PubMed 文献 · Clin Infect Dis · 2018-01-01

研究分析了312例造血干细胞移植患者,10%(31/312)移植前定植产超广谱β-内酰胺酶肠杆菌科细菌(ESBL-E)。定植者中32%(10/31)发生ESBL-E菌血症,非定植者仅0.4%(1/281)(P < .001)。所有血流分离株均对左氧氟沙星耐药,且与定植株基因型一致。

要点

  • 移植前定植ESBL-E者32%(10/31)发生ESBL-E菌血症,非定植者0.4%(1/281)。
  • 定植ESBL-E对左氧氟沙星敏感率25%,对头孢吡肟9%,对哌拉西林-他唑巴坦84%,对美罗培南97%。
  • 所有血流ESBL-E均对左氧氟沙星耐药,且与定植株基因型一致。

核心结论

  • 移植前定植左氧氟沙星耐药ESBL-E并接受左氧氟沙星预防的HSCT受者,中性粒细胞减少期间来自定植株的菌血症发生率高。
  • 评估中性粒细胞减少患者的ESBL-E定植可能有助于优化经验性抗菌治疗。

研究设计与样本

  • 2014年4月至2016年9月,对接受HSCT的患者在入院时及此后每周采集肛周拭子。
  • 共分析312例患者,包括212例异基因和100例自体HSCT受者。
  • 患者在中性粒细胞减少期间接受左氧氟沙星预防。
  • 拭子接种于选择性琼脂,对头孢曲松耐药肠杆菌科细菌进行抗菌药物敏感性试验、表型ESBL检测和β-内酰胺酶基因聚合酶链反应。
  • 对发生ESBL-E菌血症患者的定植株和血流分离株进行多位点序列分型和脉冲场凝胶电泳。

主要发现

  • 10%(31/312)的患者移植前有ESBL-E定植。
  • 定植ESBL-E的敏感率:左氧氟沙星25%,头孢吡肟9%,哌拉西林-他唑巴坦84%,美罗培南97%。
  • 31例移植前定植ESBL-E的患者中,10例(32%)在移植住院期间发生ESBL-E菌血症,而非定植的281例中仅1例(0.4%)发生(P < .001)。
  • 所有血流ESBL-E均对左氧氟沙星耐药,且同一患者的定植株和血流分离株基因型一致。

临床怎么用

  • 评估中性粒细胞减少患者的ESBL-E定植可能有助于优化经验性抗菌治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bacteremia caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is associated with inadequate empirical therapy and substantial mortality in neutropenic patients. Strategies are needed to identify neutropenic patients at high risk of these infections. METHODS: From April 2014 to September 2016, we collected perianal swabs, both at admission and weekly thereafter, from patients undergoing hematopoietic stem cell transplantation (HSCT). Patients received prophylactic levofloxacin while neutropenic. Swabs were plated onto selective agar, colonies were identified and underwent antimicrobial susceptibility testing, and phenotypic ESBL testing and polymerase chain reaction for β-lactamase genes were performed on ceftriaxone-resistant Enterobacteriaceae. We then determined the prevalence of pre-transplant ESBL-E colonization and risk of ESBL-E bacteremia. Colonizing and bloodstream isolates from patients with ESBL-E bacteremia underwent multilocus sequence typing and pulsed-field gel electrophoresis. RESULTS: We analyzed 312 patients, including 212 allogeneic and 100 autologous HSCT recipients. Ten percent (31/312) of patients had pre-transplant ESBL-E colonization. Susceptibility rates of colonizing ESBL-E were: levofloxacin, 25%; cefepime, 9%; piperacillin-tazobactam, 84%; and meropenem, 97%. Of 31 patients colonized with ESBL-E pre-transplant, 10 (32%) developed ESBL-E bacteremia during their transplant admission, compared to 1 (0.4%) of 281 patients not colonized with ESBL-E (P < .001). All bloodstream ESBL-E were levofloxacin-resistant and colonizing and bloodstream isolates from individual patients had identical genotypic profiles. CONCLUSIONS: HSCT recipients who are colonized with levofloxacin-resistant ESBL-E pre-transplant and receive levofloxacin prophylaxis have high rates of bacteremia from their colonizing strain during neutropenia. Assessing for ESBL-E colonization in neutropenic patients could lead to optimization of empirical antibacterial therapy.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Satlin MJ, Chavda KD, Baker TM, et al. Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2018. PMID: 29701766. doi:10.1093/cid/ciy363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。